Last reviewed · How we verify
Lubricating Eye Drop
Lubricating eye drops provide artificial tears that coat and moisturize the ocular surface to relieve dryness and irritation.
Lubricating eye drops provide artificial tears that coat and moisturize the ocular surface to relieve dryness and irritation. Used for Dry eye syndrome / keratoconjunctivitis sicca, Ocular irritation and discomfort.
At a glance
| Generic name | Lubricating Eye Drop |
|---|---|
| Also known as | Soothe® XP |
| Sponsor | Allergan |
| Drug class | Artificial tear / lubricating agent |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Lubricating eye drops are topical formulations containing hydrophilic polymers, electrolytes, and/or oils that mimic natural tear composition. They form a protective film over the cornea and conjunctiva, reducing evaporation and friction while providing comfort and promoting healing of dry or irritated ocular tissues.
Approved indications
- Dry eye syndrome / Keratoconjunctivitis sicca
- Ocular irritation and discomfort
Common side effects
- Transient blurred vision
- Eye irritation or stinging
- Allergic reaction (rare)
Key clinical trials
- Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant (PHASE3)
- SYSTANE® PRO vs. MIEBO™ in Dry Eye Disease (PHASE4)
- A Study to Investigate the Effect of 0.003% AR-15512 on Subjects With Dry Eye Disease (PHASE3)
- A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression (PHASE2)
- FLuorometholone as Adjunctive MEdical Therapy for TT Surgery (FLAME) Trial (PHASE3)
- A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B) (PHASE1, PHASE2)
- Traditional Chinese Medicine Ultrasonic Atomization Treatment for Dry Eye Disease (NA)
- Improved Efficacy of Selective Laser Trabeculoplasty With the Addition of Rocklatan Post-treatment vs Artificial Tears Post-treatment
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |